Revance Therapeutics Inc (NASDAQ: RVNC) kicked off on Friday, down -11.32% from the previous trading day, before settling in for the closing price of $5.30. Over the past 52 weeks, RVNC has traded in a range of $2.30-$9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 815.27% over the past five years. While this was happening, its average annual earnings per share was recorded 50.79%. With a float of $95.08 million, this company’s outstanding shares have now reached $104.18 million.
Let’s look at the performance matrix of the company that is accounted for 597 employees. In terms of profitability, gross margin is 69.55%, operating margin of -111.95%, and the pretax margin is -116.26%.
Revance Therapeutics Inc (RVNC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.74%, while institutional ownership is 65.82%. The most recent insider transaction that took place on Apr 16 ’24, was worth 9,096. In this transaction Chief Commercial Officer of this company sold 2,392 shares at a rate of $3.80, taking the stock ownership to the 114,864 shares. Before that another transaction happened on Mar 18 ’24, when Company’s President sold 9,211 for $5.04, making the entire transaction worth $46,446. This insider now owns 167,550 shares in total.
Revance Therapeutics Inc (RVNC) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.63 earnings per share (EPS), lower than consensus estimate (set at -0.85) by -0.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Take a look at Revance Therapeutics Inc’s (RVNC) current performance indicators. Last quarter, stock had a quick ratio of 3.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Revance Therapeutics Inc (NASDAQ: RVNC) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 2.73 million. As of the previous 9 days, the stock’s Stochastic %D was 41.84%. Additionally, its Average True Range was 0.22.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 55.17%, which indicates a significant increase from 2.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.84% in the past 14 days, which was lower than the 125.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.85, while its 200-day Moving Average is $4.69. Nevertheless, the first resistance level for the watch stands at $5.13 in the near term. At $5.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.79. If the price goes on to break the first support level at $4.47, it is likely to go to the next support level at $4.25. Assuming the price breaks the second support level, the third support level stands at $3.81.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
The company with the Market Capitalisation of 489.65 million has total of 104,449K Shares Outstanding. Its annual sales at the moment are 234,040 K in contrast with the sum of -323,990 K annual income. Company’s last quarter sales were recorded 65,390 K and last quarter income was -37,470 K.
